125 related articles for article (PubMed ID: 27051119)
1. Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function.
Cortés-Telles A
Lung India; 2016; 33(2):228-31. PubMed ID: 27051119
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
[TBL] [Abstract][Full Text] [Related]
3. Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.
Atug O; Akin H; Alahdab YO; Ceyhan B; Tozun N; Ozdogan O
Cases J; 2009 Mar; 2():6464. PubMed ID: 20181162
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C].
Ji FP; Li ZX; Deng H; Xue HA; Liu Y; Li M
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):667-70. PubMed ID: 19403391
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
Perry CM; Jarvis B
Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.
Kaneko R; Ogawa M; Iwata T; An Y; Nakagawa M; Kusayanagi S; Kamisago S; Umeda T; Sato Y
Clin J Gastroenterol; 2009 Aug; 2(4):296-299. PubMed ID: 26192429
[TBL] [Abstract][Full Text] [Related]
8. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chen YC; Lu SN; Lin MC
Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
10. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
11. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
[TBL] [Abstract][Full Text] [Related]
12. Interstitial pneumonitis after treatment for hepatitis C virus infection.
Botnaru V; Munteanu O; Rusu D
Pneumologia; 2015; 64(1):46-50. PubMed ID: 26016056
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
14. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
17. [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b].
Rocca P; Dumortier J; Tanière P; Duperret S; Vial T; Cottin V; Delafosse B; Scoazec JY; Boillot O
Gastroenterol Clin Biol; 2002 Apr; 26(4):405-8. PubMed ID: 12070414
[TBL] [Abstract][Full Text] [Related]
18. Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a.
Martins RS; Machado JA; Teixeira R
Rev Soc Bras Med Trop; 2012 Oct; 45(5):655-6. PubMed ID: 23152355
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
